According to data and analytics company, GlobalData, pharmaceutical sales within the age-related macular degeneration (AMD) markets will soar to $11.5 billion by the year 2026. Read more


Amgen and Allergan have received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for the marketing authorisation of ABP 980, a biosimilar to Herceptin (trastuzumab). Read more


Allergan has revealed its proposed job losses comprising 1,000 filled positions and 400 open positions in a Securities and Exchange Commission filing as a result of the cost-cutting and restructuring programme it outlined in November. Read more


Ophthalmic Squeeze Dispenser

Courtesy of Allergan

Aptar Pharma’s innovative and patented preservative-free multidose Ophthalmic Squeeze Dispenser is now available for the first time for patients in the US prescription market using Allergan’s Restasis MultiDose 0.05%. Read more


Abbvie, Sanofi and Novo Nordisk seens as most reputable pharma companies in the UK and industry as a whole ranked third most reputable by general public Read more



Image: pio3

Last year Pfizer inked its long-rumoured deal to buy botox maker Allergan, in what was described as the biggest pharmaceuticals deal in history. As the White House cracks down on tax loopholes, Pfizer is reported to have abandoned the deal Read more


Pfizer and Allergan have entered into a definitive merger agreement that will bring Pfizer into therapeutic areas such as dermatology, eye care, gastrointestinal, neuroscience and urology Read more



Rob Wilson /

Big pharma player Pfizer has inked its long-rumoured deal to buy botox maker Allergan, in what the BBC describes as “the biggest pharmaceuticals deal in history” Read more



Tinseltown /

In the USA celebrity drug endorsements are big business – but they can land manufacturers in hot water with the FDA. Here are five celebs notorious for helping to sell drugs Read more


Allergan, a global pharmaceutical company, has completed the acquisition of Oculeve Read more